Scope is fixed at Product × Technology × Application × Channel × Region, covering seven regions and thirty countries across the biotechnology ecosystem. Units for value and volume, along with the currency basis, are defined upfront to maintain consistency across biologics, reagents, consumables, instrumentation, and bioprocessing equipment. Monthly signals feed our quarterly baselines, and forecasts run at constant FX unless scenario analysis requires another treatment due to regulatory or capacity-driven sensitivities.
We count shipments once at vendor-to-channel dispatch, ensuring GMP-manufactured lots, reagent kits, and instrument units are not double-counted. Subsidiary inventory is excluded until it enters the channel. Re-exports are reassigned to the country of final use when determinable, which is particularly important for cell culture media, enzymes, assay kits, and specialized capital equipment. Manufacturer self-consumption and bona-fide research donations are incorporated to maintain installed-base integrity for labs, manufacturing suites, and analytical systems.
ASP is captured at the distributor level, with freight, insurance, and import duties included in vendor/channel pricing. Point-of-sale taxes remain outside the scope. Outliers are normalized. Prices are weighted across international, domestic, and China-based vendors, reflecting regional mixes for reagents, CGT consumables, bioreactors, single-use assemblies, and analytical systems. Bulk chemicals and bioprocess intermediates follow bulk distributor pricing.
Brand share is calculated as Brand Value ÷ Category Value by geography and channel. In the absence of EPOS, we triangulate brand value using filings, tender outcomes, procurement records, and multi-signal proxies (SRAP, PII, RHI), calibrated to disclosed anchors and bounded by corridor tests that reflect capacity and regulatory approvals.
At FMI, trade flows are compiled using HS codes relevant to biotechnology inputs, reagents, biologics, instruments, and intermediates. Mirror-stat checks are applied to detect gaps. Adjustments are made for re-exports through known logistics hubs, FOB/CIF valuation differences, and reclassification events affecting biologics, enzymes, plasmids, chromatography media, and bioprocess hardware. Series are time-aligned and currency-normalized. Apparent consumption closes as Production + Imports − Exports ± Stock Change, incorporating safety stocks common in GMP and research environments.
Revenue and volume are allocated across direct, distributor/wholesale, pharmacy/specialty (for regulated therapeutics and diagnostic kits), e-commerce for research-grade reagents, and tender/government pathways for public research institutes and hospitals. We model channel margin stacks to account for reagent markups, service-wrapped instrumentation, and contract manufacturing channels. Leakage through grey or parallel movement of reagents and diagnostics is estimated via guardrails and anomaly detection on pricing, availability, and catalog footprints.
Biotechnology supply chains are mapped from input to end-use across upstream raw materials, single-use components, bioreactor and filtration hardware, reagents, instrumentation, and finished biologics. We assess capacity, utilization, lead times, yield loss, scrap rates, lane reliability, and inventory policies across GMP and research environments. Concentration indices and single points of failure; common in media, resins, enzymes, and vector manufacturing—are stress-tested under demand surges or supply shocks. Supplier scorecards track quality, on-time delivery, batch consistency, cost variance, and risk metrics.
Method 1: Regression-based models use predictors drawn from production volumes, utilization rates in bioprocessing, trade flows in reagents and intermediates, capex cycles in biomanufacturing, regulatory approvals, and price corridors. Stability checks, residual diagnostics, structural break handling, and backtesting support model reliability.
Method 2: Driver growth-rate models apply weighted driver growth to audited baselines. We tune weights to realized outcomes influenced by clinical trial progressions, regulatory shifts, funding cycles, and capacity expansion milestones. Revisions occur with driver rebases or when shocks impact GMP output or research activity.
Triangulation uses Product Category Analysis, n-per-Population intensity for diagnostics and therapy adoption, and Economic Envelope guardrails to ensure scenarios stay feasible under research budgets, manufacturing constraints, and regulatory timelines. Outputs include value, volume, installed base, and price scenarios with confidence bands.
Regression accuracy is evaluated using MAPE supported by diagnostics and stability tests. Growth-rate models undergo correlation checks and backtesting with volatility-based tolerance bands calibrated to biotechnology variability, including trial outcomes, regulatory shifts, and supply chain dependencies. Reconciliation closes apparent consumption, and we test price corridors, FX exposure, and capacity constraints. A dual-analyst review is mandatory, and all revisions are logged with clear rationale.
Value = Units × ASP; Installed Base = Σ Shipments − Retirements; Apparent Capacity = Production / Capacity Factor; Brand Share = Brand Value ÷ Category Value; Channel Mix = Channel Revenue ÷ Total; Export–Import Balance = Exports − Imports.
UN Comtrade/ITC Trade Map; Eurostat/PRODCOM; US Census/BEA/BLS; OECD; IEA/EIA/USGS/UNCTADstat; FAOSTAT/USDA; FDA/EMA/PMDA/CDSCO; ClinicalTrials.gov/WHO ICTRP; OICA/ACEA/SIAM; EDGAR/SEMI/GSMA/3GPP; EU TED/SAM.gov; public retail signals (filings, store locators, circulars, app stores, public social). Lineage cards display pull dates, access type, transforms, confidence tier, and caveats.
Quarterly baselines with monthly micro-updates for high-frequency shifts; rapid shock notes for policy/outage/recall/price spikes. Deliverables include executive memo, workbook/models, 16:9 dashboards with lineage, and a change log. Optional: weekly SRAP/PII/RHI tiles for retail.
Methodology
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
